Kalydeco 150 MG tablet 56S
Ended Awarded Last action
- Contract number
- SPE2DR26FHKX4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $143,093
Award facts
- Contract value 100% obligated
- $143,093.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $143,093.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 56 tablets of Kalydeco 150 mg. The award, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to support recurring medical supply needs of military healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the federal military medical supply chain, with its extensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's PPV-G GEN V contract, designated SPE2DR and valued at up to $499,999,999, was awarded on November 13, 2025, with a completion date of December 31, 2036, and includes a 30-month base period with three 30-month option periods. The contractor's established performance across numerous delivery orders demonstrates its capability to fulfill diverse and specialized pharmaceutical requirements for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FHKX4?
SPE2DR26FHKX4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FHKX4 worth?
The government has obligated $143,093 on SPE2DR26FHKX4.
Is contract SPE2DR26FHKX4 an order under another contract?
Yes. SPE2DR26FHKX4 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKX4 competed?
The extent of competition for SPE2DR26FHKX4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award